Efficacy and Safety of Tenofovir Alafenamide (TAF) and Tenofovir Disoproxil Fumarate (TDF) Followed by TAF in Chronic Hepatitis B Patients of East Asian Ethnicity Following 5 Years of Treatment
Authors:
- Grace Lai-Hung WongGWGrace Lai-Hung Wong
- Edward GaneEGEdward Gane
- Calvin Q PanCPCalvin Q Pan
- Scott FungSFScott Fung
- Mang M MaMMMang M Ma
- Namiki IzumiNINamiki Izumi
- Seng Gee LimSLSeng Gee Lim
- Wan-Long ChuangWCWan-Long Chuang
- Rajiv MehtaRMRajiv Mehta
- Young-Suk LimYLYoung-Suk Lim
- Leland J YeeLYLeland J Yee
- John F FlahertyJFJohn F Flaherty
Open Access
- 12 August 2025
- journal article
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 63 (1) , 132-144
Abstract
Background: Tenofovir alafenamide (TAF) has shown non‐inferior efficacy to tenofovir disoproxil fumarate (TDF), with superior bone and renal safety. Aim: To characterise 5‐year TAF efficacy and safety in patients of East Asian ethnicity from pivotal Phase 3 studies. Methods: Patients were randomised (2:1) to receive TAF or TDF for up to 3 years of double‐blind treatment, followed by open‐label TAF. Patients either continued TAF or switched from TDF to TAF at Week 96 (TDF → TAF 3 years) or Week 144 (TDF → TAF 2 years) of treatment. Efficacy endpoints (virologic, biochemical and serologic) and safety were assessed. Results: Among 591 patients of East Asian ethnicity (TAF, n = 401; TDF → TAF 3 years, n = 84; TDF → TAF 2 years, n = 106), high rates of virologic control were achieved (89%, 94% and 92%, respectively) at Year 5 (missing = failure analysis). At Year 5, rates of alanine aminotransferase normalisation (85%, 90% and 78%) and hepatitis B e antigen loss (36%, 43% and 44%) were similar. Following the switch from TDF to TAF, changes in fasting lipid parameters were consistent with removal of the known lipid‐lowering effect of TDF. However, changes in the total cholesterol to high‐density lipoprotein ratio (marker of cardiovascular risk) were minimal and comparable in all groups by Year 5. Renal and bone parameters improved after switching. Conclusions: Through 5 years, rates of virologic suppression were high in East Asian patients treated with TAF or switched from TDF to TAF. TAF and TDF were well tolerated, with improved renal and bone safety observed in patients switching from TDF to TAF.Keywords
Funding Information
- Gilead Sciences
This publication has 57 references indexed in Scilit:
- Tenofovir alafenamide is associated with improved alanine aminotransferase and renal safety compared to tenofovir disoproxil fumarateJournal of Medical Virology, 2022
- An Aging Population of Chronic Hepatitis B With Increasing Comorbidities: A Territory‐Wide Study From 2000 to 2017Hepatology, 2019
- Long-term efficacy and safety of tenofovir disoproxil fumarate in Chinese patients with chronic hepatitis B: 5-year resultsHepatology International, 2019
- Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidanceHepatology, 2018
- Clinical response to long-term tenofovir monotherapy in Korean chronic hepatitis B patientsClinica Chimica Acta, 2017
- The efficacy and safety comparison between tenofovir and entecavir in treatment of chronic hepatitis B and HBV related cirrhosis: A systematic review and Meta-analysisInternational Immunopharmacology, 2017
- Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 updateHepatology International, 2015
- Seven-Year Efficacy and Safety of Treatment with Tenofovir Disoproxil Fumarate for Chronic Hepatitis B Virus InfectionDigestive Diseases and Sciences, 2014
- Long-Term Treatment with Tenofovir in Asian-American Chronic Hepatitis B Patients Is Associated with Abnormal Renal Phosphate HandlingDigestive Diseases and Sciences, 2014
- Viral Suppression and Cirrhosis Regression with Tenofovir Disoproxil Fumarate in Asians with Chronic Hepatitis BDigestive Diseases and Sciences, 2014